Young Investigator Award

2012 RECIPIENTS
Abby Rosenberg, MD

“Understanding Resilience in Parents of Children with Cancer”

Adam Schmitt, MD

“Long Non-coding RNA Modulation of the p53 Response to DNA Damage”

Aihua Yen, MD

“Novel Approaches to Eliminate Androgen Receptor Action in Prostate Cancer”

Alexander Drilon, MD

“A Phase II Trial of Subcutaneous Bortezomib and Analysis of the NF-kB Pathway in a Molecularly-Selected Cohort of Advanced Previously-Treated KRAS G12D-Mutant Lung Adenocarcinoma”

Alice Mims, MD

“Manipulating MicroRNA Expression to Improve Outcome in AML”

Andrew Lane, MD

“Defining chromosome 21 loci that promote lymphoid leukemogenesis”

Antonio Giordano, MD, PhD

“Single-nucleus sequencing to investigate circulating tumor cell origin in breast cancer patients”

Arjun Balar, MD

“Phase II Study of Gemcitabine and Pazopanib in Cisplatin Ineligible Patients with Metastatic Urothelial Cancer and the Potential Impact of Inherited Genetic Variation on Outcomes”

Breelyn Wilky, MD

“The Role of RNA Helicase DDX3 in Ewing’s Sarcoma Stem Cells”

Charles Ferte, MD

“Implementation of the Gene Expression Barcode method to produce more powerful prognostic signatures for patients diagnosed with lung cancer”

Christopher Kanakry, MD

“Novel, single-agent, short-course GVHD prophylaxis with post-transplant cyclophosphamide: mechanisms and GVT implications”

Christos Vaklavas, MD

“Targeting IRES Mediated Translation in Cancer Therapeutics”

Courtney DiNardo, MD

“DNA methylation profiling and prognostication in de novo acute myeloid leukemia (AML)”

David Van Mater, MD, PhD

“A role for injury in sarcomagenesis”

Edward Allan Sison, MD

“Targeting the Bone Marrow Stromal Microenvironment in Pediatric Leukemias”

Emily Ko, MD

“Metformin for the Treatment of Endometrial Hyperplasia”

Eric Kim, MD

“CTR1 Transporter Dysregulation in Platinum Resistance in Non-small Cell Lung Cancer”

Florencia McAllister, MD

“Role of inflammatory cells in early pancreatic tumorigenesis”

Gabrielle Rocque, MD

“Automatic Palliative Care Consultation for Hospitalized Cancer Patients: Improving the Quality of End-of-life Care”

Irene Brana, MD

“Identification of Potential Biomarkers of Response or Resistance to Novel Combinations of Molecularly Targeted Anticancer Agents Using Genomically Characterized Human Tumor Xenografts”

James Harding, MD

“A Phase 2 Trial of Vorinostat in Patients with Metastatic Uveal Melanoma: Exploring the Molecular Effects and Therapeutic Implications of Histone Deacetylase Inhibition in Uveal Melanomas”

James Murphy, MD

“Inequality, utilization and cost of palliative radiotherapy: a population-based study”

Jason Westin, MD

“Targeting Chemotherapy Resistance in Diffuse Large B-Cell Lymphoma: Defining the Role of the PI3K/Akt/mTOR Pathway”

Jens Lohr, MD

“Defining Novel Oncogenic Drivers in Multiple Myeloma”

Jianjun Gao, MD, PhD

“Investigating IFN-g signaling as a critical pathway for anti-CTLA-4 therapy mediated anti-tumor responses”

Justin Wahlstrom, MD

“Mechanisms of Chemotherapy Resistance in Childhood T-ALL”

Kasey Leger, MD

“Evaluation of microRNAs as novel markers of cardiotoxicity in children undergoing anthracycline therapy for pediatric cancer”

Katherine Van Loon, MD, MPH

“The Relationship of Serum 25-hydroxyvitamin D Levels to Overall Survival in Advanced Pancreatic Cancer”

Kevin McDonnell, MD

“Genetic Analysis of Multiple Colon Neoplasias in a Novel 5q Deletion Syndrome: Unveiling the Molecular Evolution of Synchronous Colon Cancer and the Implications for Rational Targeted Therapy Design”

Lincoln Nadauld, MD, PhD

“An Integrated Approach to the Validation of Novel Gastric Oncogenes”

Ludmila Martin, MD

“Combined Inhibition of the MAPK and PI3K/Akt Pathways in Advanced Biliary Cancers”

Marcela Maus, MD, PhD

“Pre-clinical evaluation of a novel chimeric antigen receptor directed to the cancer-testis antigen NY-ESO-1”

Martin Voss, MD

“Predictive Tissue Biomarkers for mTOR Inhibitors in Advanced Renal Cell Carcinoma (RCC)”

Nikhil Wagle, MD

“Identification of mechanisms of therapeutic resistance in BRAF-mutant melanoma by systematic genomic profiling”

Priscilla Brastianos, MD

“Genomic Characterization of Brain Metastases from Breast Cancer”

Rahul Agaarwal, MD

“The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer”

Ronac Mamtani, MD

“Thiazolidinediones (TZDs) and the risk of bladder cancer”

Ryan Corcoran, MD, PhD

“Identification of Novel Targeted Therapy Combination Strategies for KRAS Mutant Cancers”

Sadhna Vora, MD

“Fructose Metabolism as a Mechanism of Acquired Resistance to Phosphatidylinositol 3-kinase (PI3K) Inhibitors in Breast Cancer”

Stephen Chung, MD

“Characterization of CD99 as a Therapeutic Target in MDS and AML”

Syed Kazmi, MBBS, MD, MS

“Modulation of Colorectal Cancer Stem Cells with Chemotherapy”

Tina Dasgupta, MD, PhD

“Enhancing the Efficacy of Radiotherapy in Gliomas”

Vamsidhar Velcheti, MD

“Prognostic and Predictive value of Programmed Death-1 ligands in Non-small Cell Lung Cancer”

Yanis Boumber, MD, PhD

“The Role of Epigenetics in Tumor Progression in Non-Small Cell Lung Cancer”

Zachary Hector-Word, MD

“Geriatric Assessment to Predict Toxic Events in Older Patients with Non-Hodgkin Lymphoma with Pilot Study of Initial Low Dose Prednisone and Rituximab”